RGNCY-0063 (SNU-BP PPAR-γ agonist)
SNU-BP is a novel small molecule that inhibits lipopolysaccharide (LPS)-induced nitric oxide production in microglia. SNU-BP inhibits pro-inflammatory cytokines and inducible nitric oxide synthase in LPS-stimulated microglia and potentiated interleukin-4 induced arginase-1 expression. SNU-BP specifically activates PPAR-γ and not PPARδ- nor PPAR-α, confirming that PPAR-γ is the specific target protein for SNU-BP. The anti-inflammatory effect of SNU-BP is attenuated by pharmacological and genetic inhibition of PPAR-γ . SNU-BP also induced an anti-inflammatory phenotype in astrocytes by inhibiting pro-inflammatory nitric oxide and TNF-α while increasing anti-inflammatory genes such as arginase-1 and Ym-1. SNU-BP increases the M2-like phenotype of neuroglia. Importantly, SNU-BP produced an anti-inflammatory response in the LPS-injected mouse brain demonstrating a protective potential for neuroinflammatory diseases.
Systematic Name: 2-(4-(5-(1-((benzyl(phenylcarbamoyl)carbamoyl)oxy)propyl)isoxazol-3-yl)phenoxy)-2-methylpropanoic acid
Mol Wt: 557.60
Tags: No, small molecule, Microglia, SNU-BP, RGNCY-0063, Neuroinflammation, astrocyte, glia, PPAR-gamma, lipopolysaccharide, nitric oxide, LPS